Related Experiment Video
Updated: Aug 28, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice
Elizabeth Ann Doyle1, Stuart Alan Weinzimer2, William Tamborlane2
1Yale University School of Nursing, Orange, Connecticut.
Insights
Diabetic ketoacidosis (DKA) is uncommon in youth using insulin pumps, but often preventable. Education on pump troubleshooting is crucial, especially for teens with high A1C levels, even those using continuous glucose monitors (CGMs).
Area of Science:
- Pediatric Endocrinology
- Metabolic Disorders
- Diabetes Technology
Background:
- Diabetic ketoacidosis (DKA) remains a significant complication in youth with type 1 diabetes (T1D).
- Insulin pump therapy and continuous glucose monitors (CGMs) are increasingly used to manage T1D in pediatric populations.
- Understanding DKA incidence and contributing factors in this cohort is essential for effective prevention strategies.
Purpose of the Study:
- To report recent incidence data for DKA in young insulin pump users with T1D.
- To evaluate the impact of CGMs on DKA rates among these patients.
- To identify common causes of DKA events in this population.
Main Methods:
- Retrospective chart review of insulin pump users (under 26 years) from December 2019 to June 2021.
- Analysis of 591 patients, with a focus on DKA event occurrence, severity, and patient characteristics.
- Comparison of DKA severity between CGM users and non-users.
Main Results:
- DKA incidence was 3.16 events per 100 patient-years among 591 pump users.
- Most DKA events occurred in adolescents (85.7% aged 12-19) with high A1C (mean 10.2%) and longer diabetes duration.
- Pump site failure (57.1%) was the most common cause; CGM use did not significantly alter DKA severity.
Conclusions:
- DKA events are relatively infrequent in youth using insulin pumps but are often preventable.
- Reinforced DKA prevention education is vital, particularly for adolescents with elevated A1C levels.
- Even CGM users require frequent educational reinforcement regarding DKA prevention and pump troubleshooting.
Purpose:
This purpose of the study was to describe recent diabetic ketoacidosis (DKA) incidence data in youth with type 1 diabetes using insulin pumps and the impact of continuous glucose monitors (CGMs) on DKA rates.
Methods:
DKA data were obtained through a retrospective chart review of insulin pump users (ages <26 years) between December 2019 and June 2021 in an academic pediatric endocrinology practice where 68% of patients were pump users.
Results:
Among 591 pump patients, 28 events occurred (3.16 events per 100 patient-years). Mean age was 13.6±3.4 years; 85.7% ranged from 12 to 19 years. Mean A1C was 10.2±2.3%, diabetes duration was 6.1±4.0 years, and 57.1% used CGM. Admission pH levels ranged between 7.0 and 7.31, with 28.6% of events classified as "moderate" and 46.4% "severe." There was no significant difference in the DKA severity between those who wore a CGM and those who did not (ie, pH, serum bicarbonate, mentation alteration, length of stay, intensive care unit admission, and hospital admission). DKA events were attributed to concurrent illness (10.7%), insulin omission (14.3%), pump site failure (57.1%), or other pump malfunctions (14.3%).
Conclusion:
DKA events in pump-treated patients were relatively uncommon; most episodes occurred in adolescents with higher A1C levels, and notably, most events could have been avoided if users followed standard troubleshooting guidelines. Thus, DKA prevention education should be reinforced at each encounter, particularly for teens with higher A1C levels. Moreover, more than 50% of those with DKA episodes wore a CGM, suggesting that pump users using CGM require frequent reinforcement of this education and that the development of such educational materials is critical.
More Related Videos
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

